MENU

LCTX Stock Lineage Cell Therapeutics (LCTX, $0.47) Stochastic Oscillator left the oversold zone on April 11, 2025

A.I.dvisor
at Tickeron.com
Loading...
LCTX - Lineage Cell Therapeutics
Stochastic signal
Bullish Trend
Odds of UP Trend
Tickeron
Stochastic signal
Price: $0.4698
Daily change: +$0.0598 (+14.59%)
Daily volume: 951.5K
Capitalization: $107.3M
Industry: Biotechnology
This is a signal that LCTX's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options. A.I.dvisor identified 75 similar cases where LCTX's stochastic oscillator exited the oversold zone, and of them led to successful outcomes. Odds of Success:

LCTX's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for LCTX turned positive on April 11, 2025. Looking at past instances where LCTX's MACD turned positive, the stock continued to rise in of 56 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LCTX's RSI Oscillator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on April 22, 2025. You may want to consider a long position or call options on LCTX as a result. In of 114 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where LCTX advanced for three days, in of 212 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 63 cases where LCTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LCTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

LCTX broke above its upper Bollinger Band on April 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for LCTX entered a downward trend on April 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.452) is normal, around the industry mean (14.056). P/E Ratio (0.000) is within average values for comparable stocks, (63.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (10.504) is also within normal values, averaging (252.992).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. LCTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LCTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
LCTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, and neurological conditions

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2173 Salk Avenue
Phone
+1 442 287-8990
Employees
75
Web
https://www.lineagecell.com